A New Horizon for Lymphoma Patients: InnoCare's HIBRUCA Approved in Singapore for Marginal Zone Lymphoma

InnoCare Pharma, a leading biopharmaceutical company, has announced a momentous breakthrough in cancer treatment, securing approval from the Singapore Health Sciences Authority (HSA) for HIBRUCA (orelabrutinib). This landmark decision allows HIBRUCA to be used for the treatment of adult patients with relapsed or refractory Marginal Zone Lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.

This approval marks a significant step forward for patients in Singapore battling this rare and often challenging form of non-Hodgkin lymphoma.

MZL is a type of slow-growing lymphoma that originates from B-cells, often presenting with a chronic course and a propensity for relapse. For those whose disease has returned or not responded to initial treatments, the availability of new, targeted therapies like HIBRUCA offers a vital and much-needed beacon of hope.

HIBRUCA is an innovative, highly selective Bruton's Tyrosine Kinase (BTK) inhibitor.

BTK plays a crucial role in the B-cell receptor signaling pathway, which is essential for the growth and survival of various B-cell malignancies, including MZL. By precisely targeting and inhibiting BTK, orelabrutinib effectively disrupts these pathways, leading to the control or reduction of cancer cells with potentially fewer off-target side effects compared to less selective agents.

This latest approval further solidifies orelabrutinib's growing global footprint.

HIBRUCA has previously received approval in Singapore for other indications, specifically for adult patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), and for adult patients with relapsed or refractory Mantle Cell Lymphoma (MCL). In its home market of China, orelabrutinib is approved for both r/r CLL/SLL and r/r MCL, demonstrating a consistent track record of efficacy and safety across multiple B-cell malignancies.

The expansion of HIBRUCA's approved indications in Singapore underscores InnoCare Pharma's unwavering commitment to addressing unmet medical needs and providing transformative therapeutic options to patients worldwide.

This new treatment offers clinicians in Singapore an important additional tool in their arsenal against lymphoma, potentially improving outcomes and quality of life for those living with relapsed or refractory MZL.

As InnoCare Pharma continues its research and development efforts, the approval of HIBRUCA for MZL in Singapore stands as a testament to the power of targeted therapy and the relentless pursuit of innovative solutions in the fight against cancer, bringing renewed optimism to the patient community and healthcare professionals alike.